Your session is about to expire
← Back to Search
STEMVAC Vaccine for Lung Cancer
Study Summary
This trial is testing a vaccine made of DNA that targets proteins that help lung cancer cells grow. The vaccine is given with a substance that helps create a stronger immune response.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 87 Patients • NCT04326920Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have recovered from major infections or surgeries and don't have other serious illnesses.I am 18 years old or older.I have brain metastases that are stable, untreated, or not worsening, and I haven't taken steroids for 2 weeks.My cancer can be measured by scans and has grown even after radiation.I am willing to have two biopsies during the study.My kidney function is normal or near normal.I have serious heart conditions, including unstable chest pain or heart failure.I am a woman who can have children and have a negative pregnancy test.I had another cancer but was treated successfully over 2 years ago with no signs of return.My liver function tests are within the required limits.I have a cancer site that can be biopsied, which hasn't been previously treated with radiation or has shown growth after radiation.Your lymphocyte count should be at least 800 cells per cubic millimeter within 30 days before your first vaccination.My cancer has specific genetic changes but I can't use or have tried all approved treatments.I have an autoimmune disease but only take medication for short-term issues or hormone replacement.I haven't taken systemic steroids in the last 28 days, except with pemetrexed.I cannot take medications similar to rhuGM-CSF due to health reasons.I am fully active or restricted in physically strenuous activity but can do light work.Your white blood cell count must be at least 3000 per cubic millimeter within 30 days before the first vaccination.Your total bilirubin level should be no higher than 1.5 mg/dl within 30 days before the first vaccination.I finished 4 cycles of specific cancer treatment without my cancer getting worse.I have been diagnosed with stage IV non-squamous NSCLC.You are expected to live for at least 6 more months.Your hemoglobin level is at least 9 grams per deciliter within 30 days before the first vaccination.I have had 2 or fewer cycles of pembrolizumab and pemetrexed and can continue this treatment.Your platelet count is at least 75,000 per cubic millimeter within the last 30 days.
- Group 1: Arm I (STEMVAC, sargramostim)
- Group 2: Arm II (sargramostim)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Has Sargramostim received regulatory clearance from the Food and Drug Administration?
"Our internal evaluation of sargramostim's safety indicates that it falls under a score of 2, as Phase 2 trials are limited in both efficacy and safety data."
Are individuals still able to join the current clinical experiment?
"Clinicaltrials.gov's information indicates that this trial, which began on November 21st 2022 and was recently updated October 21st 2022 is not actively recruiting participants at the moment. Nevertheless, there are currently 1,496 other medical trials searching for volunteers."
What is the principal aim of this research endeavor?
"This clinical trial, which lasts for up to a year, aims to compare the change in CD8+ TIL between two different arms. Secondary objectives include determining overall survival rates through Kaplan-Meier estimations and 95% CIs at certain time points using Greenwood's formula; assessing changes from baseline of T-cell activation markers and Type I immune cells with Two-sample T-tests or Wilcoxon tests; as well as measuring the magnitude of Th1 STEMVAC specific immune response via IFN-gamma ELISPOTs before comparing it between both vaccine and adjuvant alone groups with a t test if no"
Share this study with friends
Copy Link
Messenger